RT Journal Article
T1 Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
T2 Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria.
A1 Gago-Veiga, A B
A1 Santos-Lasaosa, S
A1 Cuadrado, M L
A1 Guerrero, Á L
A1 Irimia, P
A1 Láinez, J M
A1 Leira, R
A1 Pascual, J
A1 Sanchez Del Río, M
A1 Viguera, J
A1 Pozo-Rosich, P
K1 Botulinum neurotoxin A
K1 Chronic migraine
K1 Consenso
K1 Consensus
K1 Guidelines
K1 Migraña crónica
K1 OnabotulinumtoxinA
K1 Preventive treatment
K1 Recomendaciones
K1 Toxina botulínica A
K1 Tratamiento preventivo
AB OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM.
YR 2017
FD 2017-11-21
LK http://hdl.handle.net/10668/11841
UL http://hdl.handle.net/10668/11841
LA en
LA es
DS RISalud
RD Apr 12, 2025